Consort Gets FDA Approval For Its Integrated Dose Counter
30 Avril 2012 - 9:04AM
Dow Jones News
Consort Medical PLC (CSRT.LN), a U.K. maker of medical devices
for inhaled drug delivery and self-injection, Monday said that the
U.S. Food and Drug Administration has approved the first product to
use its Bespak division's Integrated Dose Counter, or IDC.
The IDC is being used with Teva Pharmaceutical Industries Ltd.'s
(TEVA) QNASL Nasal Aerosol for the treatment of nasal symptoms
associated with seasonal allergic rhinitis and perennial allergic
rhinitis in adults and adolescents.
Consort said its Bespak business, which develops devices to
deliver drugs to sufferers of asthma and chronic obstructive
pulmonary disease, has been developing its IDC for a number of
years.
The device provides patients with an easy-to-read indication of
how many doses are left inside the canister.
Consort Medical's shares closed Friday at 656.0 pence.
-By Jana Weigand, Dow Jones Newswires; 44-20-7842-9314;
jana.weigand@dowjones.com